TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients
Heartflow announced late-breaking TCT 2026 data showing CT-guided PCI planning using its technology was non-inferior to IVUS on the P4 trial's one-year primary endpoint of target-vessel failure (4.1% vs. 4.6%) in 1,105 patients, with results simultaneously published in NEJM. CT guidance also delivered efficiency gains: 17-minute shorter median procedure time (46 vs. 63 minutes), roughly 12% lower contrast volume, and more than doubled use of advanced calcium modification.
Key figures
- Drug Name
- Heartflow PCI Navigator
- Phase Of Trial
- Phase 4 (P4 randomized trial)
- P4 patients
- 1105
- Patients managed
- over 750,000
- Institutions adopted
- more than 1,800
- Calcium modification use
- 9.2% vs. 3.8%
- Contrast volume reduction
- approximately 12% (median 150 mL vs. 170 mL)
- Navigate pci cohort patients
- 203
- Procedure time ct vs ivus min
- 46 vs. 63 (17-minute / 27% reduction)
- Navigate pci plan modification rate
- approximately 70%
- P4 primary endpoint 12mo tvf ct vs ivus
- 4.1% vs. 4.6%
- Braveheart subclinical plaque prevalence
- 72%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.